Galectin Therapeutics Inc. (GALT)

[biotech2010]

I don't consider myself part of the 'peanut gallery'-I have heavily researched GALT's history and drug development and thought I had a very good grasp about what to expect from them. That, obviously, was completely wrong because of the way they have presented themselves over the past several years.

I am a firm believer in 'under promising and over performing' while the GALT team just thinks they can talk a good game and not back it up with results and data.

Traber believes that the FX trial was done for the right reasons, I believe they screwed it up (as they did the Phase 1 Cohort 2 data result) by creating unrealistic expectations to the public.

If I had been running GALT the whole FX trial would have been couched in terms of 'this is an exploratory trial, we have no confidence that the results will be significant but our investigator believes it needs to be done. The CX trial is a much more important undertaking and, if you want to be a shareholder, be prepared to wait until the end of 2017 for something that we feel has a strong chance of success'

I just don't get the statements they are making that 'the CX trial needs to be completed regardless of the FX results'. Of course it needs to be completed! The company is worth less than a Grande Mocha Frappacino without good results.